Elżbieta P.
- Country
- Poland
- Department
- 2801: Klinika Hematologii
Research Overview
- Long-term Safety of Asciminib in Patients With Philadelphia Chromosome-Positive CML or ALL Continuing From Parent Studies
- Phase 3 Multicenter Double-Blind Randomized Study of Ivosidenib and Azacitidine in Untreated IDH1-Mutated Acute Myeloid Leukemia Patients Aged ≥18 Years
- Phase 3 Study of Quizartinib with Chemotherapy in FLT3-ITD Negative Acute Myeloid Leukemia Patients
Data & Insights
Has run more than one trial at 66 of 184 partner sites.
Specializations
Leukemia Research Focus
This investigator specializes in advancing treatments for various forms of acute myeloid leukemia (AML), with particular attention to both newly diagnosed and relapsed/refractory cases.
- Relapsed/Refractory AML Management
- FLT3-ITD Negative AML Treatment
- IDH1-Mutated AML Therapy
The investigator's work extends to innovative therapeutic approaches for these challenging conditions.
Molecular Targeted Therapies
The investigator focuses on developing and evaluating targeted therapeutic agents for specific genetic mutations in leukemia patients.
- Novel Agent Development
- Combination Therapy Approaches
- Mutation-Specific Treatments
Their research encompasses both single-agent and combination treatment strategies.
Chronic Myeloid Leukemia
The investigator has expanded their expertise to include chronic phase chronic myeloid leukemia (CML-CP), particularly focusing on treatment-resistant variants.
- T315I Mutation Studies
- Novel CML Therapeutics
- Molecular Response Assessment
Their work includes evaluating innovative treatments for various CML mutations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.